FDA Approves Trutakna for Primary IgA Nephropathy, Offering New Hope for Kidney Disease
The FDA has granted accelerated approval for Trutakna (atacicept-vymj), a new treatment for primary IgA nephropathy, marking a significant advance for patients with this rare kidney disease that can progress to kidney failure.
FDA Accelerated Approval Brings New Treatment Option
FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy on July 7, 2026. This approval represents a major milestone for patients suffering from IgA nephropathy (IgAN), also known as Berger's disease, a progressive form of kidney inflammation.
Understanding IgA Nephropathy
Primary IgA nephropathy is the most common form of glomerulonephritis worldwide, characterized by abnormal deposits of immunoglobulin A in the kidneys. The disease causes progressive kidney damage and can lead to chronic kidney disease and eventual kidney failure requiring dialysis or transplantation. Many patients lack effective treatment options, and the condition can silently progress with minimal symptoms in early stages.
How Trutakna Works
Trutakna (atacicept) functions as a selective costimulation modulator that targets B-cell activation. Vera Therapeutics and Bristol Myers Squibb are seeking Accelerated Approval for atacicept for the treatment of immunoglobulin A nephropathy (IgAN), also known as Berger's disease. By modulating immune responses specific to IgA nephropathy, the drug aims to slow or halt progression of kidney disease.
Clinical Impact and Patient Outlook
The accelerated approval pathway allows Trutakna to reach patients more quickly based on promising preliminary data, with the expectation that additional confirmatory trials will follow. For the IgA nephropathy community, this represents validation that targeted immune therapies can address a previously intractable disease. Patients who receive early treatment may have improved long-term kidney function and delayed progression toward dialysis or transplantation.